Fundraising Fox
Sab
NASDAQ: SABSMiami Beach, US · Founded 2014 · 88 employees on LinkedIn · 1 known investors
Find your way into Sab
Sign up to see every warm intro you have to Sab
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sab team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SAB BIO is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, using genetically engineered transchromosomic cattle to produce therapeutic candidates. The company has advanced its lead candidate SAB-142 for Type 1 Diabetes into Phase 2b clinical trials.
Founders & leadership
Sab was founded in 2014 by Eddie J Sullivan.
EJ
Eddie J SullivanCo-Founder and PresidentEddie J Sullivan is the founder of SAB BIO, a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G therapies using genetically engineered transchromosomic cattle. He brings executive experience in biotechnology with expertise in FDA regulation, vaccines, and infectious diseases.
RB
Russell BeyerChief Financial Officer, EVP2021–2023Russell Beyer is an Executive Officer at SAB Biotherapeutics who previously held senior finance and operations roles at Fortune 100 pharmaceutical and technology companies including AstraZeneca, Teva Pharmaceuticals, World Fuel Services, and Hewlett Packard, with experience in business transformation, merger integration, and international operations across Europe, Latin America, and the United States.
SJ
Samuel J. ReichChief Executive OfficerSamuel J. Reich is Chief Executive Officer of SAB Biotherapeutics, which he joined in 2021 following its combination with Big Cypress Acquisition Group, where he served as Chief Executive Officer and Chief Financial Officer. He previously co-founded Biscayne Neurotherapeutics in 2011 (sold to Supernus Pharmaceuticals in 2018) and founded Acuity Pharmaceuticals in 2002 (acquired by Opko Health). Reich holds a B.A. in Biochemistry from Clark University and a M.S. from the University of Pennsylvania, where he conducted doctoral research on gene therapy applications, and is an inventor on multiple U.S. and international patents related to RNA interference therapeutics.
Board
JS
Jeffrey SpragensBoard director
AM
Andrew MoinBoard director
JS
Jay SkylerBoard director
EL
Erick LuceraBoard director
WP
William PolvinoBoard director
KE
Katie ElliasBoard director
DL
David LinkBoard director
SG
Scott GibersonBoard director
CH
Christine HamiltonBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$182.5M disclosed across 2 rounds · 2023–2025
▶$175MraisedAug 2025 · 17 investors · BiotechnologyRule 506(b)
▶$175MraisedAug 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MoinDirector
- Jay SkylerDirector
- Erick LuceraDirector
- Samuel ReichExecutive Officer, Director
- William PolvinoDirector
- Katie ElliasDirector
- Eddie SullivanExecutive Officer, Director
- Jeffrey SpragensDirector
- David LinkDirector
- Scott GibersonDirector
- Christine HamiltonDirector
- Offering amount
- $175M
- Amount sold
- $175M
- Sales commissions
- $10.5M
- Placement agents
- Oppenheimer & Co. Inc., Chardan Capital Markets, LLC, Leerink Partners LLC, UBS SECURITIES LLC
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$7.5MraisedOct 2023 · 13 investors · BiotechnologyRule 506(b)
▶$7.5MraisedOct 2023 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Russell BeyerExecutive Officer
- Erick LuceraDirector
- David Charles LinkDirector
- Samuel ReichExecutive Officer, Director
- Eddie J. SullivanExecutive Officer, Director
- William PolvinoDirector
- Christine HamiltonDirector
- Scott GibersonDirector
- Andrew MoinDirector
- Jeffrey G. SpragensDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- Sales commissions
- $450K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $199.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.4M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Sab do?
- SAB BIO is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, using genetically engineered transchromosomic cattle to produce therapeutic candidates. The company has advanced its lead candidate SAB-142 for Type 1 Diabetes into Phase 2b clinical trials.
- Who founded Sab?
- Sab was founded by Eddie J Sullivan in 2014.
- Who are Sab's investors?
- Sab's investors include JDRF T1D Fund.
- How much funding has Sab raised?
- Sab has disclosed $182.5M raised across 2 rounds.
- Where is Sab headquartered?
- Sab is headquartered in Miami Beach, US.